Rahway, New Jersey-based Merck & Co., Inc. (MRK) is an international healthcare company that offers human health pharmaceuticals across various areas, including Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, and other brands. Valued at a market cap of $358.9 billion, the company also provides veterinary pharmaceuticals, vaccines, and health management solutions and services.
MRK is expected to release its Q3 2026 earnings on Thursday, Oct. 29, before the market opens. Ahead of the event, analysts expect the company’s EPS to be $2.12 on a diluted basis, down 17.8% from $2.58 in the year-ago quarter. The company has exceeded Wall Street’s EPS estimates in each of its last four quarters, which is impressive.